Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
Patrick Schöffski(KU Leuven), Shreyaskumar Patel(The University of Texas MD Anderson Cancer Center), Sun Young Rha(Yonsei University), Hans Gelderblom(Leiden University Medical Center), Sebastian Bauer(Science for Life Laboratory), Bartosz Chmielowski(UCLA Health), Jean‐Yves Blay(Université Claude Bernard Lyon 1), Peter Hohenberger(University of Mannheim), Giovanni Grignani(Candiolo Cancer Institute), George D. Demetri(Dana-Farber Cancer Institute), Antoîne Italiano(Memorial Sloan Kettering Cancer Center), Robert G. Maki(Memorial Sloan Kettering Cancer Center), Edwin Choy(Massachusetts General Hospital), Sant P. Chawla(Sarcoma Oncology Center), David R. D’Adamo(Eisai (United States)), Axel Le Cesne(Institut Gustave Roussy), Matthew Guo(Eisai (United States)), Veridiana Pires de Camargo(Instituto do Câncer do Estado de São Paulo)
Cited by 766
Related Papers
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
|New England Journal of Medicine|2002|4.4k
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
Cremophor EL
|European Journal of Cancer|2001|1.6k